L-DOPA Antibody

ELISA: L-DOPA Antibody [NBP3-06881] - ELISA plate is coated with 100 uL of L-DOPA-carrier protein conjugate at 10 ug/mL. The coated ligand is detected with at concentrations ranging from 360 ng/mL down to 1.3 ng/mL.

Dot Blot: L-DOPA Antibody [NBP3-06881] - Analysis of 100 ng BSA-conjugated levodopa, using levodopa antibody at 1:4000, 1:8000, and 1:16000.

• Reactivity: All-NA
• Applications: DB, ELISA
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Concentration: 0.35 mg/ml

L-DOPA Antibody Summary

• Immunogen: The immunogen used to generate this antibody corresponds to Levodopa (L-DOPA)
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Purity: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Dot Blot
  • ELISA 1:1000-1:10000
• Application Notes: Dot blot-Assay dependent.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7), 20% Glycerol, 1% BSA
• Preservative: 0.025% Proclin 300
• Concentration: 0.35 mg/ml
• Purity: Antigen Affinity-purified

Alternate Names for L-DOPA Antibody

• 3 4 dihydroxy L phenylalanine
• L dihydroxyphenylalanine
• Levodopa

Background

L Dopa is an intermediate in dopamine biosynthesis. Clinically, L Dopa is used in the management of Parkinson's disease. It is used as a prodrug to increase dopamine levels since it is able to cross the blood-brain barrier whereas dopamine itself cannot. Once L Dopa has entered the central nervous system (CNS), it is metabolised to dopamine by aromatic L amino acid decarboxylase. This also occurs in the peripheral tissues, causing adverse effects and decreasing the available dopamine to the CNS, so it is standard practice to co administer a peripheral DOPA decarboxylase inhibitor and often a catechol-O-methyl transferase (COMT) inhibitor. The antiserum was tested using the free floating PAP technique on rat dopaminergic areas. The anti-conjugated L-DOPA antibodies gave a good staining between 1/2000-1/5000 dilution in these areas.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for L-DOPA Antibody (NBP3-06881)(1)

Publication using NBP3-06881

• He S, Liu J, Xue Y et al. Sympathetic Nerves Coordinate Corneal Epithelial Wound Healing by Controlling the Mobilization of Ly6Chi Monocytes From the Spleen to the Injured Cornea Investigative ophthalmology & visual science 2023-09-01 [PMID: 37682569] (Western Blot, Mouse)